MedicaSafe, Inc.
Mark Morrison has a significant work history in the medical device industry. Mark currently serves as the Sr. Vice President of Electrical Engineering at MedicaSafe, Inc. since May 2020, and previously held the role of Vice President of Engineering at the same company from 2019 to May 2020. Prior to that, Mark worked at West Pharmaceutical Services as a Sr. Hardware Engineer, where they contributed to the development of innovative electronic and wireless sensor systems for drug delivery devices. Mark also has experience at Teva Pharmaceuticals as a Sr. Electrical Engineer, specializing in breath actuated inhalers and MEMS sensor technologies. Before that, Mark worked at Philips Sleep and Respiratory Care as a Sr. Electrical/Project Engineer, focusing on the design and manufacturing of nebulizers and compliance monitoring devices. Mark started their career at i-Stat Corporation as an Engineering Project Manager, where they oversaw the design and manufacturing of blood analyzers for hospital Point-of-Care settings.
Mark Morrison received a Bachelor of Science degree in Electrical Engineering from Cornell University.
This person is not in any teams
This person is not in any offices
MedicaSafe, Inc.
MedicaSafe creates innovative technologies for guiding patients through high-stakes outpatient medication therapies. These solutions also address needs for regular patient assessment, tracking, and medication access management, enabling creation of comprehensive treatment management systems that reduce labor and costs while improving outcomes. Technology / Differentiation A patent-protected approach, developed with funding from the NIH, facilitates patient behavioral modification and patient tracking. The system can be geared to correct underuse of medication or, alternatively, limit drug access to prevent overuse. Market / Customers Lack of adherence/compliance in a clinical setting is estimated to produce 125,000 deaths and $100 billion in health care costs annually. MedicaSafe is targeting areas of specific applicability such as: 1) Risk Management (REMS) 2) High-Value Chronic Treatments 3) Clinical Trials